MSP-1 Block 2 represents a promising target for malaria vaccine development, since several seroepidemiological studies have shown that individuals with antibodies to MSP-1 Block 2 have reduced risk of subsequent clinical malaria episodes [25]–[29]. Here, ATAD1 is linked to malaria.